采用3个 successive 风险分层胰腺切除术临床路径降低术后全局期费用
单中心回顾性队列研究纳入814例连续胰腺切除术患者,比较3个迭代版本的风险分层临床路径(V1、V2、V3)。结果显示Accordion 3级及以上并发症逐版下降(V1 28.4%、V2 22.7%、V3 15.3%),中位住院日缩短,90天全局期围术期费用下降32%(费用比V1 12.6、V2 10.9、V3 8.6),主要来自指数住院费用降低。
要点
- 3个迭代版本路径的Accordion 3级及以上并发症逐版下降:V1 28.4%、V2 22.7%、V3 15.3%。
- 90天全局期围术期费用下降32%,费用比V1 12.6、V2 10.9、V3 8.6。
- 指数住院费用降幅最大(-31%:费用比9.4、8.3、6.5),其中病房或床位费降55%、药费降61%(均P<0.001)。
核心结论
- 3次迭代的风险分层胰腺切除术临床路径改进与32%的全局期费用节省相关,主要由指数住院费用降低驱动。
- 作者认为这一成功的学习型医疗系统模型可在其他开展腹部肿瘤手术的机构进行外部验证。
研究设计与样本
- 单中心回顾性队列研究,纳入连续胰腺切除术患者,路径分为3个迭代版本:V1(2016年10月至2019年1月)、V2(2019年2月至2020年10月)、V3(2020年11月至2022年2月)。
- 使用收费代码汇总机构数据,并调整为2022年不变美元值;主要终点为围术期总费用,即胰腺切除术、住院护理、再入院和90天全局门诊护理费用之和。
- 医院专有成本以所有医院手术的平均成本为分母转换为比值。
主要发现
- 共814例患者,V1包含363例、V2 229例、V3 222例。
- Accordion 3级及以上并发症逐版下降:V1 28.4%、V2 22.7%、V3 15.3%。
- 中位住院日缩短:V1 6天(四分位距[IQR] 5至8)、V2 5天(IQR 4至6)、V3 5天(IQR 4至6),再入院未增加。
- 90天全局期围术期费用下降32%:费用比V1 12.6、V2 10.9、V3 8.6。
- 指数住院费用降低与最大节省相关(-31%:费用比9.4、8.3、6.5);门诊护理费用持续下降(1.58、1.41、1.04);再入院与全部门诊费用合计的出院后总费用下降(3.17、2.59、2.13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We hypothesized that iterative revisions of our original 2016 risk-stratified pancreatectomy clinical pathways would be associated with decreased 90-day perioperative costs. STUDY DESIGN: From a single-institution retrospective cohort study of consecutive patients with 3 iterations: "version 1" (V1) (October 2016 to January 2019), V2 (February 2019 to October 2020), and V3 (November 2020 to February 2022), institutional data were aggregated using revenue codes and adjusted to constant 2022-dollar value. Grand total perioperative costs (primary endpoint) were the sum of pancreatectomy, inpatient care, readmission, and 90-day global outpatient care. Proprietary hospital-based costs were converted to ratios using the mean cost of all hospital operations as the denominator. RESULTS: Of 814 patients, pathway V1 included 363, V2 229, and V3 222 patients. Accordion Grade 3+ complications decreased with each iteration (V1: 28.4%, V2: 22.7%, and V3: 15.3%). Median length of stay decreased (V1: 6 days, interquartile range [IQR] 5 to 8; V2: 5 [IQR 4 to 6]; and V3: 5 [IQR 4 to 6]) without an increase in readmissions. Ninety-day global perioperative costs decreased by 32% (V1 cost ratio 12.6, V2 10.9, and V3 8.6). Reduction of the index hospitalization cost was associated with the greatest savings (-31%: 9.4, 8.3, and 6.5). Outpatient care costs decreased consistently (1.58, 1.41, and 1.04). When combining readmission and all outpatient costs, total "postdischarge" costs decreased (3.17, 2.59, and 2.13). Component costs of the index hospitalization that were associated with the greatest savings were room or board costs (-55%: 1.74, 1.14, and 0.79) and pharmacy costs (-61%: 2.20, 1.61, and 0.87; all p < 0.001). CONCLUSIONS: Three iterative risk-stratified pancreatectomy clinical pathway refinements were associated with a 32% global period cost savings, driven by reduced index hospitalization costs. This successful learning health system model could be externally validated at other institutions performing abdominal cancer surgery.
引用
- Azimuddin A, Tzeng CD, Prakash LR, et al. Postoperative Global Period Cost Reduction Using 3 Successive Risk-Stratified Pancreatectomy Clinical Pathways. J Am Coll Surg. 2024. PMID: 38180055. doi:10.1097/XCS.0000000000000944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。